Core A (Administrative Core) will provide coordination and oversight of all activities of the Projects and Cores, and will maximize synergistic interactions among Project Leaders, Core Directors, and laboratory personnel. The administrative component will provide fiscal management, clerical and organizational support. Core A will provide guidance for conflict resolution and resource allocation. Fiscal management will include oversight of project and core budgets in accordance with policies and procedures of Columbia University and the NIH, as well as oversight of staff appointments, salaries and fringe benefits. To facilitate integration ofthe program and effective communication among its various members, Core A will organize monthly meetings of all Program participants for research presentations. Core A will also organize executive meetings, which will be limited to the Executive Committee (Drs. Gautier, Baer, Bhagat, Symington, and Zha). Finally, Core A will establish mechanisms for review of the Program Project by the Advisory Board. Core A will also facilitate interactions between individual projects and scientific cores B/C and the facilities in place at the Herbert Irving Comprehensive Cancer Center. Core A has the following specific aims: 1) Coordination of the overall program by supporting the organization ofthe program and implementing mechanisms for effective interaction among its personnel and by coordinating the interactions between projects, cores and existing facilities at the Cancer Center;2) Review of the Program Project by the Advisory Boards to evaluate ongoing progress of each Project, review the functionality of the Cores, and provide advice on future research directions. The administrative core services are therefore an integral and essential part ofthe Program to function as an integrated, efficient unit.

Public Health Relevance

The success of this Program Project Grant involves administrative and fiscal management, and coordination between projects and cores. This core will ensure that the pace of scientific discovery will move as quickly as possible so that the program goals are met in a timely fashion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel ()
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University
New York
United States
Zip Code
Symington, Lorraine S (2016) Mechanism and regulation of DNA end resection in eukaryotes. Crit Rev Biochem Mol Biol 51:195-212
Yamamoto, Kenta; Wang, Jiguang; Sprinzen, Lisa et al. (2016) Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife 5:
Oh, Julyun; Al-Zain, Amr; Cannavo, Elda et al. (2016) Xrs2 Dependent and Independent Functions of the Mre11-Rad50 Complex. Mol Cell 64:405-415
Aparicio, Tomas; Baer, Richard; Gottesman, Max et al. (2016) MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts. J Cell Biol 212:399-408
Reczek, Colleen R; Shakya, Reena; Miteva, Yana et al. (2016) The DNA resection protein CtIP promotes mammary tumorigenesis. Oncotarget 7:32172-83
Deng, Sarah K; Chen, Huan; Symington, Lorraine S (2015) Replication protein A prevents promiscuous annealing between short sequence homologies: Implications for genome integrity. Bioessays 37:305-13
Yamamoto, K; Lee, B J; Li, C et al. (2015) Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia 29:1414-24
Chen, Huan; Donnianni, Roberto A; Handa, Naofumi et al. (2015) Sae2 promotes DNA damage resistance by removing the Mre11-Rad50-Xrs2 complex from DNA and attenuating Rad53 signaling. Proc Natl Acad Sci U S A 112:E1880-7
Deng, Sarah K; Yin, Yi; Petes, Thomas D et al. (2015) Mre11-Sae2 and RPA Collaborate to Prevent Palindromic Gene Amplification. Mol Cell 60:500-8
Sato, Mai; Rodriguez-Barrueco, Ruth; Yu, Jiyang et al. (2015) MYC is a critical target of FBXW7. Oncotarget 6:3292-305

Showing the most recent 10 out of 14 publications